nih glp 1 Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review

NEWS: NIH scientists have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now. The team identified key intracellular signaling processes in a

21.14

★★★★☆4.8 (126)

Lieutenant Governor visits NIDA IRP Clinical Program

27.14

★★★★★4.9 (98)

A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used for weight loss, such as semaglutide, may also help reduce heavy drinking in individuals

21.87

★★★★★5.0 (157)

Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society -

26.21

★★★★★4.7 (84)

The Brief A new NIH-funded study found that oral small-molecule GLP-1 drugs may reduce not only hunger but also pleasure-driven cravings by affecting the brain's reward circuitry. Researchers discovered these drugs activate

24.05

★★★★★4.9 (203)

New NIH data: Oral GLP-1s hit deeper brain reward centers than shots. 🧠 This explains why 'food noise' may vanish faster on pills: targeting cravings at the source. Full study: glp-1.reviews/blog/oral-glp1-brain-study #GLP1 #

20.11

★★★★★5.0 (176)

Figure 2, Health Canada Approval Timeline for GLP-1 Receptor Agonists by Marketed Date and NOC Dates - Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

27.73

★★★★★4.8 (132)